Navigation Links
Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Date:11/9/2011

PARIS and TARRYTOWN, N.Y., Nov. 10, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive preliminary results from the Phase 2 study program in which patients with elevated low-density lipoprotein cholesterol (LDL-C) were treated with REGN727/SAR236553.

REGN727/SAR236553 is a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).  Blocking the PCSK9 pathway is a novel mechanism for lowering LDL-C, the leading known risk factor for coronary artery disease.

One Phase 2 trial studied patients with heterozygous familial hypercholesterolemia (heFH) with elevated cholesterol (LDL-C>/=100mg/dL) despite lipid lowering therapy (statins with or without ezetemibe).  The objective of the study was to compare the effect of adding REGN727/ SAR236553 to the existing lipid lowering therapy in heFH patients.  In the primary efficacy analysis of the study, after 12 weeks of treatment, patients who received different dosing regimens of REGN727/SAR236553 achieved mean LDL-C reductions from baseline ranging from approximately 30% to greater than 65% depending on the dosing regimen of REGN727/SAR236553 compared to a mean reduction of 10% with placebo (p<0.05 for all dose groups).  Patients in the study are being followed for a total of 20 weeks for safety.

In this trial, REGN727/SAR236553 was generally well tolerated over 12 weeks.  There were no elevations in LFTs >3 times the upper limit of normal (ULN) and no cases of elevated CPK reported.  The most common adverse event was injection site reaction.  There were no serious adverse events on active treatment.  Full safety data from the 8-week po
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Now available for sale, The Armor1 Ankle Roll Guard is ... sprains by cushioning the ankle from an inversion or ... outside of any shoe type and allows the user ... protection against sprains. With customers in physical therapy, podiatry, ...
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)... Jan. 23, 2015  Mallinckrodt plc (NYSE: MNK ... approved a share repurchase program. The open-ended authorization permits ... Mallinckrodt plc ordinary shares. "Funding additional ... priorities as we continue to pursue a range of ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... 2011 GeneTex, a leading manufacturer of high ... specials on products from their large catalog containing ... damage antibodies, proteins, peptides, and research reagents.  Plus, ... quantitative measurements of proteins including cytokines, interleukins, growth ...
... Aug. 23, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) is ... result in the reduction of more than $620,000 in debt ... agreement and new consulting agreement will result in a reduction ... Endoscopy posted its financial statements for period ended June 30, ...
Cached Medicine Technology:There's an Ab for That! GeneTex Offers One of the Largest Catalogs of Antibodies 2Solos Endoscopy to Reduce Debt by Over $620,000 2
(Date:1/22/2015)... 2015 Deer Path of Huntley -- ... Day Happy Hour from 3 p.m. to 4 p.m. on Feb. ... in Huntley, Illinois, serves adults with physical disabilities between the ages ... Valentine's Day treats, games and sweetheart-themed karaoke. , For more information ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located in ... number one best large hotel for families in the United ... annual Travelers’ Choice Awards. , TripAdvisor represents the world’s ... to millions of unbiased and honest traveler reviews. The best ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... make a dramatic difference in the management of patients with ... a new study finds. // ,The study, of ... 35% of patients, said Philip W.P. Bearcroft, MD, of Cambridge ... more significant is the fact that before an MRI was ...
... the U.S., the poorer their mental health becomes.// That’s ... prevalence of psychiatric disorders among Black individuals in the ... of the American Journal of Public Health. ,David ... of Society, Human Development and Health at the Harvard ...
... from the European Molecular Biology Laboratory's (EMBL) Mouse Biology ... Olavide in Sevilla,// Spain, now for the first time ... The study, which appears in the current issue of ... involved in learning and singled out the signaling pathway ...
... genetics and law experts at the Sandra Day O’Connor ... that could dramatically// hasten the development of personalized medicine. ... American Medical Association Journal, side effects from prescription drugs ... number of these deaths could be prevented by the ...
... as Hispanic and white women in two separate clinical ... be diagnosed// with later-stage cancer and to have more-aggressive ... the study, lead researcher Wendy Woodward of the University ... examined 2,140 women participating in two clinical trials of ...
... the first place among states and union territories to enforce ... find any genetic disorder// that could lead to disabilities. ... screening of all children would be done to check any ... introduce screening shortly. ,While poor people would be ...
Cached Medicine News:Health News:Researchers Investigate Molecular Basis of Memory 2Health News:More Americans Die Due To Side Effects From Prescription Drugs Every Year: Report 2Health News:More Americans Die Due To Side Effects From Prescription Drugs Every Year: Report 3
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...
... stage hermetically sealed refrigeration system ... cabinet interior achieving -35C*. This ... TS-2000 alarm monitoring system and ... to comply with Australian Standard ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
... of use and patient comfort, our soft ... comfort and is available in a range ... fit. For hard to fit patients, MARPAC ... your specifications. Don't just take our word ...
Medicine Products: